trending Market Intelligence /marketintelligence/en/news-insights/trending/KJaXzXkj6oKIIVuT7Xn6Sw2 content esgSubNav
In This List

Axsome Therapeutics raises $23.3M from stock offering to fund drug programs

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Axsome Therapeutics raises $23.3M from stock offering to fund drug programs

Axsome Therapeutics Inc. raised about $23.3 million from a stock offering carried out with Leerink Partners LLC.

The New York-based biopharmaceutical company sold 2,881,066 shares in the offering.

Axsome intends to use the proceeds to fund the ongoing clinical development of its late-stage product candidates and for other general corporate purposes.

Just recently, the company, which develops therapies for managing central nervous system disorders, reported positive data from a mid-stage study, which showed that its medicine AXS-05 helped reduce depression symptoms in patients.